High SIRT1 expression is a negative prognosticator in pancreatic ductal adenocarcinoma

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Stenzinger, Albrecht ^a   Endris, Volker ^a   Klauschen, Frederick ^b   Sinn, Bruno ^b   Lorenz, Katja ^a   Warth, Arne ^a   Goeppert, Benjamin ^a   Ehemann, Volker ^a   Muckenhuber, Alexander ^a   Kamphues, Carsten ^b   Bahra, Marcus ^b   Neuhaus, Peter ^b   Weichert, Wilko ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Biomarker; HDAC; Pancreatic cancer; Pancreatic ductal adenocarcinoma; Sirt1

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CAMBINOL; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; GEMCITABINE; NICOTINAMIDE; PROTEIN INHIBITOR; SIRTUIN 1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER PROGNOSIS; CANCER SURVIVAL; CELL SURVIVAL; CELL VIABILITY; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG TARGETING; FLUORESCENCE ACTIVATED CELL SORTING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PROTEIN EXPRESSION; UNIVARIATE ANALYSIS;

AGED; AGED, 80 AND OVER; CARCINOMA, PANCREATIC DUCTAL; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; NAPHTHALENES; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; NIACINAMIDE; PANCREATIC NEOPLASMS; PROGNOSIS; PYRIMIDINONES; QUINAZOLINES; SIRTUIN 1;

EID: 84884764745     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-450     Document Type: Article

References (49)

1. Hong SM, Park JY, Hruban RH, Goggins M. Molecular signatures of pancreatic cancer. Arch Pathol Lab Med 2011, 135:716-27. 3107523, 21631264.
2. Hidalgo M. Pancreatic cancer. N Engl J Med 2010, 362:1605-1617. 10.1056/NEJMra0901557, 20427809.
3. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004, 363:1049-1057. 10.1016/S0140-6736(04)15841-8, 3062508, 15051286.
4. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet 2011, 378:607-20. 10.1016/S0140-6736(10)62307-0, 21620466.
5. Singh P, Srinivasan R, Wig JD. Major molecular markers in pancreatic ductal adenocarcinoma and their roles in screening, diagnosis, prognosis, and treatment. Pancreas 2011, 40:644-652. 10.1097/MPA.0b013e31821ff741, 21673535.
6. Vaziri H, Dessain K, Ng Eaton E, Imai SI, Frye RA, Pandita TK, Guarente L, Weinberg RA. hSIR2(SIRT1) Functions as an NAD-Dependent p53 Deacetylase. Cell 2001, 107:149-159. 10.1016/S0092-8674(01)00527-X, 11672523.
7. Luo J, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A, Guarente L, Gu W. Negative Control of p53 by Sir2alpha Promotes Cell Survival under Stress. Cell 2001, 107:137-148. 10.1016/S0092-8674(01)00524-4, 11672522.
8. Jeong J, Juhn K, Lee H, Kim SH, Min BH, Lee KM, Cho M, Park GH, Lee KH. SIRT1 Promotes DNA Repair Activity and Deacetylation of Ku70. Exp Mol Med 2007, 39:8-13. 10.1038/emm.2007.2, 17334224.
9. Ikenoue T, Inoki K, Zhao B, Guan KL. PTEN Acetylation Modulates Its Interaction with PDZ Domain. Cancer Res 2008, 68:6908-6912. 10.1158/0008-5472.CAN-08-1107, 18757404.
10. Dai JM, Wang ZY, Sun DC, Lin RX, Wang SQ. SIRT1 Interacts with p73 and Suppresses p73-Dependent Transcriptional Activity. J Cell Physiol 2007, 210:161-166. 10.1002/jcp.20831, 16998810.
11. Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA, Mayo MW. Modulation of NF-kappaB-Dependent Transcription and Cell Survival by the SIRT1 Deacetylase. EMBO J 2004, 23:2369-2380. 10.1038/sj.emboj.7600244, 423286, 15152190.
12. Motta MC, Divecha N, Lemieux M, Kamel C, Chen D, Gu W, Bultsma Y, McBurney M, Guarente L. Mammalian SIRT1 Represses Forkhead Transcription Factors. Cell 2004, 116:551-563. 10.1016/S0092-8674(04)00126-6, 14980222.
13. Guarani V, Deflorian G, Franco CA, Kruger M, Phng LK, Bentley K, Toussaint L, Dequiedt F, Mostoslavsky R, Schmidt MH. Acetylation-Dependent Regulation of Endothelial Notch Signalling by the SIRT1 Deacetylase. Nature 2011, 473:234-238. 10.1038/nature09917, 21499261.
14. Lim JH, Lee YM, Chun YS, Chen J, Kim JE, Park JW. Sirtuin 1 Modulates Cellular Responses to Hypoxia by Deacetylating Hypoxia-Inducible Factor 1alpha. Mol Cell 2010, 38:864-878. 10.1016/j.molcel.2010.05.023, 20620956.
15. Dioum EM, Chen R, Alexander MS, Zhang Q, Hogg RT, Gerard RD, Garcia JA. Regulation of Hypoxia-Inducible Factor 2alpha Signaling by the Stress-Responsive Deacetylase Sirtuin 1. Science 2009, 324:1289-1293. 10.1126/science.1169956, 19498162.
16. Firestein R, Blander G, Michan S, Oberdoerffer P, Ogino S, Campbell J, Bhimavarapu A, Luikenhuis S, de Cabo R, Fuchs C, Hahn WC, Guarente LP, Sinclair DA. The SIRT1 Deacetylase Suppresses Intestinal Tumorigenesis and Colon Cancer Growth. PLoS One 2008, 3:e2020. 10.1371/journal.pone.0002020, 2289879, 18414679.
17. Fan W, Luo J. Regulates UV-Induced DNA Repair through Deacetylating XPA. Mol Cell 2010, 39:247-258. 10.1016/j.molcel.2010.07.006, 20670893.
18. Kume S, Haneda M, Kanasaki K, Sugimoto T, Araki S, Isshiki K, Isono M, Uzu T, Guarente L, Kashiwagi A, Koya D. SIRT1 Inhibits Transforming Growth Factor Beta-Induced Apoptosis in Glomerular Mesangial Cells via Smad7 Deacetylation. J Biol Chem 2007, 282:151-158.
19. Zhang Y, Zhang M, Dong H, Yong S, Li X, Olashaw N, Kruk PA, Cheng JQ, Bai W, Chen J. Deacetylation of Cortactin by SIRT1 Promotes Cell Migration. Oncogene 2009, 28:445-460. 10.1038/onc.2008.388, 18850005.
20. Tissenbaum HA, Guarente L. Increased dosage of a sir-2 gene extends lifespan in Caenorhabditis elegans. Nature 2001, 410:227-230. 10.1038/35065638, 11242085.
21. Viswanathan M, Guarente L. Regulation of Caenorhabditis elegans lifespan by sir-2.1 transgenes. Nature 2011, 477:E1-2. 10.1038/nature10440, 21938026.
22. Rogina B, Helfand SL. Sir2 mediates longevity in the fly through a pathway related to calorie restriction. Proc Natl Acad Sci U S A 2004, 101:15998-6003. 10.1073/pnas.0404184101, 528752, 15520384.
23. Burnett C, Valentini S, Cabreiro F, Goss M, Somogyvári M, Piper MD, Hoddinott M, Sutphin GL, Leko V, McElwee JJ, Vazquez-Manrique RP, Orfila AM, Ackerman D, Au C, Vinti G, Riesen M, Howard K, Neri C, Bedalov A, Kaeberlein M, Soti C, Partridge L, Gems D. Absence of effects of Sir2 overexpression on lifespan in C. elegans and Drosophila. Nature 2011, 477:482-485. 10.1038/nature10296, 3188402, 21938067.
24. Brooks CL, Gu W. How does SIRT1 affect metabolism, senescence and cancer?. Nat Rev Cancer 2009, 9:123-128. 10.1038/nrc2562, 2857763, 19132007.
25. Marshall GM, Liu PY, Gherardi S, Scarlett CJ, Bedalov A, Xu N, Iraci N, Valli E, Ling D, Thomas W, van Bekkum M, Sekyere E, Jankowski K, Trahair T, Mackenzie KL, Haber M, Norris MD, Biankin AV, Perini G, Liu T. SIRT1 Promotes N-Myc Oncogenesis through a Positive Feedback Loop Involving the Effects of MKP3 and ERK on N-Myc Protein Stability. PLoS Genet 2011, 7:e1002135. 10.1371/journal.pgen.1002135, 3116909, 21698133.
26. Serrano M. SIRT1 Transgenic and Cancer Models 2011, Orlando, FL: Proceedings of the 102nd Annual Meeting of the AACR, Presentation SY11-03.
27. Saunders LR, Verdin E. Sirtuins: critical regulators at the crossroads between cancer and aging. Oncogene 2007, 26:5489-5504. 10.1038/sj.onc.1210616, 17694089.
28. Zhao G, Cui J, Zhang JG, Qin Q, Chen Q, Yin T, Deng SC, Liu Y, Liu L, Wang B, Tian K, Wang GB, Wang CY. SIRT1 RNAi knockdown induces apoptosis and senescence, inhibits invasion and enhances chemosensitivity in pancreatic cancer cells. Gene Ther 2011, 18:920-928. 10.1038/gt.2011.81, 21677689.
29. Sobin LH, Gospodarowicz MK, Wittekind C. UICC: TNM classification of malignant tumors 2009, Oxford: Wiley-Blackwell, 7.
30. WHO Classification of Tumours of the Digestive System (IARC WHO Classification of Tumours), The International Agency for Research on Cancer (Author) 2010, Bosman FT, Carneiro F, Hruban RH, Theise ND, 4.
31. Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y, Tran H, Ross SE, Mostoslavsky R, Cohen HY, Hu LS, Cheng HL, Jedrychowski MP, Gygi SP, Sinclair DA, Alt FW, Greenberg ME. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 2004, 303:2011-2015. 10.1126/science.1094637, 14976264.
32. Ehemann V, Hashemi B, Lange A, Otto HF. Flow cytometric DNA analysis and chromosomal aberrations in malignant glioblastomas. Cancer Lett 1999, 138:101-106. 10.1016/S0304-3835(98)00383-8, 10378780.
33. Wauters E, Sanchez-Arévalo Lobo VJ, Pinho AV, Mawson A, Herranz D, Wu J, Cowley MJ, Colvin EK, Njicop EN, Sutherland RL, Liu T, Serrano M, Bouwens L, Real FX Biankin AV, Rooman I. Sirtuin-1 Regulates Acinar-to-Ductal Metaplasia and Supports Cancer Cell Viability in Pancreatic Cancer. Cancer Res 2013, 66:2357-2367.
34. Heltweg B, Gatbonton T, Schuler AD, Posakony J, Li H, Goehle S, Kollipara R, Depinho RA, Gu Y, Simon JA, Bedalov A. Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res 2006, 66:4368-4377. 10.1158/0008-5472.CAN-05-3617, 16618762.
35. Simic P, Zainabadi K, Bell E, Sykes DB, Saez B, Lotinun S, Baron R, Scadden D, Schipani E, Guarente L. SIRT1 regulates differentiation of mesenchymal stem cells by deacetylating β-catenin. EMBO Mol Med 2013, 5:430-40. 10.1002/emmm.201201606, 3598082, 23364955.
36. Hong EH, Yun HS, Kim J, Um HD, Lee KH, Kang CM, Lee SJ, Chun JS, Hwang SG. Nicotinamide phosphoribosyltransferase is essential for interleukin-1beta-mediated dedifferentiation of articular chondrocytes via SIRT1 and extracellular signal-regulated kinase (ERK) complex signaling. J Biol Chem 2011, 286:28619-31. 10.1074/jbc.M111.219832, 3151103, 21697093.
37. Chen HC, Jeng YM, Yuan RH, Hsu HC, Chen YL. SIRT1 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma and its expression predicts poor prognosis. Ann Surg Oncol 2012, 19:2011-9. 10.1245/s10434-011-2159-4, 22146883.
38. Huffman DM, Grizzle WE, Bamman MM, Kim JS, Eltoum IA, Elgavish A, Nagy TR. SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res 2007, 67:6612-8. 10.1158/0008-5472.CAN-07-0085, 17638871.
39. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, Lu L, Irvin D, Black KL, Yu JS. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 2006, 5:67. 10.1186/1476-4598-5-67, 1697823, 17140455.
40. Nalls D, Tang SN, Rodova M, Srivastava RK, Shankar S. Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells. PLoS One 2011, 6e:24099.
41. Pramanik D, Campbell NR, Karikari C, Chivukula R, Kent OA, Mendell JT, Maitra A. Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice. Mol Cancer Ther 2011, 10:1470-1480. 10.1158/1535-7163.MCT-11-0152, 3154495, 21622730.
42. Li L, Wang L, Li L, Wang Z, Ho Y, McDonald T, Holyoake TL, Chen W, Bhatia R. Activation of p53 by SIRT1 Inhibition Enhances Elimination of CML Leukemia Stem Cells in Combination with Imatinib. Cancer Cell 2012, 21:266-81. 10.1016/j.ccr.2011.12.020, 3285436, 22340598.
43. Barton CM, Staddon SL, Hughes CM, Hall PA, O'Sullivan C, Klöppel G, Theis B, Russell RC, Neoptolemos J, Williamson RC, et al. Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. Br J Cancer 1991, 64:1076-1082. 10.1038/bjc.1991.467, 1977874, 1764370.
44. Ruggeri B, Zhang SY, Caamano J, DiRado M, Flynn SD, Klein-Szanto AJ. Human pancreatic carcinomas and cell lines reveal frequent and multiple alterations in the p53 and Rb-1 tumor-suppressor genes. Oncogene 1992, 7:1503-1511.
45. Zhao G, Qin Q, Zhang J, Liu Y, Deng S, Liu L, Wang B, Tian K, Wang C. Hypermethylation of HIC1 Promoter and Aberrant Expression of HIC1/SIRT1 Might Contribute to the Carcinogenesis of Pancreatic Cancer. Ann Surg Oncol 2012, doi:DOI 10.1245/s10434-012-2364-9. May 3. [Epub ahead of print].
46. Huang S, Benavente S, Armstrong EA, Li C, Wheeler DL, Harari PM. p53 modulates acquired resistance to EGFR inhibitors and radiation. Cancer Res 2011, 71:7071-7079. 10.1158/0008-5472.CAN-11-0128, 3229180, 22068033.
47. Lowery MA, O'Reilly EM. Genomics and pharmacogenomics of pancreatic adenocarcinoma. Pharmacogenomics J 2012, 12:1-9. 10.1038/tpj.2011.52, 22186617.
48. Byles V, Zhu L, Lovaas JD, Chmilewski LK, Wang J, Faller DV, Dai Y. SIRT1 induces EMT by cooperating with EMT transcription factors and enhances prostate cancer cell migration and metastasis. Oncogene 2012, 31:4619-29. 10.1038/onc.2011.612, 22249256.
49. Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 2007, 25:84-90. 10.1038/nbt1272, 17211407.